Zobrazeno 101 - 110
of 235
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Jose Luis Calleja, Eric Lawitz, Jean-François Dufour, Martin Bonacci, Salvatore Petta, Michael Allison, Mary E. Rinella, Philippe Mathurin, Lixia Wang, Syed Q. Hussaini, Arun J. Sanyal, Aldo Trylesinki, Luna Zaru, Leigh MacConell, Paul Marotta, Vlad Ratziu, Rodolphe Anty, Reshma Shringarpure, Ingolf Schiefke, Manal F. Abdelmalek, Kris V. Kowdley, Bruce Wong, Quentin M. Anstee
Publikováno v:
Gastroenterology. 158:S-1406
In the REGENERATE interim analysis, obeticholic acid (OCA) improved liver histology in patients with non-alcoholic steatohepatitis (NASH). Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels may be associated with fibr
Autor:
Grace S. Park, Manal F. Abdelmalek, Karen Lai, Gerardo Rodriguez, Jérôme Boursier, Sven Francque, Naim Alkhouri, Sam E. Moussa, Eduardo B. Martins, Ziad Younes, Alexander Hodge
Publikováno v:
Gastroenterology. 158:S-1446
Autor:
Ransi M. Somaratne, Stephen J. Rossi, Stephen A. Harrison, Mark Jaros, Manal F. Abdelmalek, Lei Ling, Alex M. DePaoli
Publikováno v:
Diabetes. 67
Background: NGM282 is an engineered variant of human FGF-19 that retains bile acid and metabolic regulatory activities while eliminating the tumorigenic effects of FGF-19. Multiple preclinical models showed improvements in NASH liver histology simila
Autor:
Brent A. Neuschwander-Tetri, Arun J. Sanyal, Manal F. Abdelmalek, Kris V. Kowdley, Beatrice Ferguson, Reshma Shringarpure, Arthur J. McCullough, Norah A. Terrault, Srinivasan Dasarathy, Rohit Loomba, Naga Chalasani, David Shapiro
Publikováno v:
Liver international : official journal of the International Association for the Study of the Liver. 39(5)
BACKGROUND & AIMS Non-invasive biomarkers are needed for monitoring changes in liver histology in patients with non-alcoholic steatohepatitis (NASH). Obeticholic acid (OCA) was shown to improve fibrosis in patients with NASH in the FLINT trial; a pos
Autor:
Mohammad Shadab Siddiqui, Goro Yamada, Raj Vuppalanchi, Mark Van Natta, Rohit Loomba, Cynthia Guy, Danielle Brandman, James Tonascia, Naga Chalasani, Brent Neuschwander-Tetri, Arun J. Sanyal, Daniela Allende, Srinivasan Dasarathy, Arthur J. McCullough, Revathi Penumatsa, Jaividhya Dasarathy, Joel E. Lavine, Manal F. Abdelmalek, Mustafa Bashir, Stephanie Buie, Anna Mae Diehl, Christopher Kigongo, Mariko Kopping, David Malik, Dawn Piercy, Oscar W. Cummings, Samer Gawrieh, Linda Ragozzino, Kumar Sandrasegaran, Elizabeth M. Brunt, Theresa Cattoor, Danielle Carpenter, Janet Freebersyser, Debra King, Jinping Lai, Brent A. Neuschwander-Tetri, Joan Siegner, Susan Stewart, Susan Torretta, Kristina Wriston, Maria Cardona Gonzalez, Jodie Davila, Manan Jhaveri, Kris V. Kowdley, Nizar Mukhtar, Erik Ness, Michelle Poitevin, Brook Quist, Sherilynn Soo, Brandon Ang, Cynthia Behling, Archana Bhatt, Michael S. Middleton, Claude Sirlin, Maheen F. Akhter, Nathan M. Bass, Ryan Gill, Bilal Hameed, Jacqueline Maher, Norah Terrault, Ashley Ungermann, Matthew Yeh, Sherry Boyett, Melissa J. Contos, Sherri Kirwin, Velimir A.C. Luketic, Puneet Puri, Jolene Schlosser, Mohammad S. Siddiqui, Leslie Yost-Schomer, Kathryn Fowler, David E. Kleiner, Edward C. Doo, Sherry Hall, Jay H. Hoofnagle, Jessica J. Lee, Patricia R. Robuck, Averell H. Sherker, Rebecca Torrance, Patricia Belt, Jeanne M. Clark, John Dodge, Michele Donithan, Erin Hallinan, Milana Isaacson, Mariana Lazo, Jill Meinert, Laura Miriel, Jacqueline Smith, Michael Smith, Alice Sternberg, Mark L. Van Natta, Annette Wagoner, Laura A. Wilson, Katherine Yates
Publikováno v:
Clin Gastroenterol Hepatol
BACKGROUND & AIMS: Noninvasive methods are needed to determine disease stage in patients with nonalcoholic fatty liver disease (NAFLD). We evaluated the diagnostic performance of several widely available fibrosis models for the assessment of hepatic
Autor:
Brian L. Wiens, Jeffrey Vest, Guruprasad P. Aithal, Arun J. Sanyal, Star Seyedkazemi, Vincent Wai-Sun Wong, Zachary Goodman, Laurent Fischer, Rohit Loomba, Eric Lefebvre, Vlad Ratziu, Frank Tacke, Kris V. Kowdley, Geoffrey C. Farrell, Manal F. Abdelmalek, Pamela Vig, Liza Melchor-Khan, Antonio Craxì, Scott L. Friedman, Krzysztof Simon, Juan Caballería, Stephen A. Harrison, Sven Francque
Publikováno v:
Hepatology (Baltimore, Md.), vol 67, iss 5
Hepatology
Hepatology (Baltimore, Md.)
Hepatology
Hepatology (Baltimore, Md.)
The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd279267e63b246d0eb39c5941a3a85b
https://nottingham-repository.worktribe.com/file/927093/1/Friedman_et_al-2018-Hepatology.pdf
https://nottingham-repository.worktribe.com/file/927093/1/Friedman_et_al-2018-Hepatology.pdf
Autor:
Stephanie Noviello, Stephen A. Harrison, Arun J. Sanyal, Rohit Loomba, Rose C. Christian, Edgar D. Charles, Manal F. Abdelmalek, Sudeep Kundu, Brent A. Neuschwander-Tetri, Eric Lawitz, Yi Luo, Dina Halegoua-DeMarzio
Publikováno v:
Lancet (London, England). 392(10165)
Summary Background Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. In this phase 2a study
Publikováno v:
Journal of Hepatology. 70:e782-e783
Autor:
Zac Anchi Chang, Claude B. Sirlin, Benjamin Wildman-Tobriner, Stephen J. Rossi, Manal F. Abdelmalek, Mustafa R. Bashir, Cynthia A. Moylan, Michael M. Middleton, Omar Flores
Publikováno v:
Gastroenterology. 155(5)
BACKGROUND & AIMS: Patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) often require histologic assessment via liver biopsy. Magnetic resonance imaging (MRI)-based methods for measuring liver triglycerides ba
Publikováno v:
Journal of Functional Morphology and Kinesiology, Vol 2, Iss 4, p 35 (2017)
Nonalcoholic Fatty Liver Disease (NAFLD) is a growing health epidemic in developed countries with increased prevalence in obese and diabetic populations. Exercise is an established and essential component of lifestyle modification for NAFLD disease m